We work Hard to get you posted with latest updates

http://We%20work%20Hard%20to%20get%20you%20posted%20with%20latest%20updates

Spend time learning about the different aspects of that topic from experts in the field.

ADC AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy

Unwrap our new Directory

http://Unwrap%20our%20new%20Directory

Directory

Home
Pharma
Bio-Pharma
MedTech
Veterinary
Cosmetics
Food
.Clinical
.Tech
.edu
.gov
M&A
.VC

GIRK4

Advertisement

cGxPJobs Banner

Bayer Advances GIRK4 Inhibitor Into Phase II for Atrial Fibrillation

BERLIN — September 9, 2026 Bayer announced the initiation of a global Phase II clinical trial of BAY 3670549,...

By cGxPwire Editor
September 11, 2026

Read More

Advertisement

cGxPJobs

Recent Posts

01

Bio-Pharma

CONNECTA Therapeutics Secures €3.1M for Fragile X Program
September 11, 2026
02

.Clinical

Teitur Trophics Advances TT-P34 Toward Phase II in Parkinson’s
September 11, 2026
03

.Clinical

EPIK Biosciences Expands Ketamine and DXM Drug Portfolio
September 11, 2026
04

.Clinical

Disc Medicine Advances DISC-3405 in Polycythemia Vera
September 11, 2026
05

Bio-Pharma

BioLineRx and Hemispherian Present GLIX1 Data
September 11, 2026

Advertisement

Copyright © 2026 cGxP.wire | Made by 3styler

Directory

Home
Pharma
Bio-Pharma
MedTech
Veterinary
Cosmetics
Food
.Clinical
.Tech
.edu
.gov
M&A
.VC

Start typing and press Enter to search

Loading Comments...

Write a Comment...

Email (Required)

Name (Required)

Website